Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors (TKIs) imatinib mesylate and nilotinib represents a successful application of molecularly targeted anticancer therapy. However, the effect of TKIs on leukemic stem cells remains incompletely understood. On the basis of a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tang, Min, Gonen, Mithat, Quintas-Cardama, Alfonso, Cortes, Jorge, Kantarjian, Hagop, Field, Chani, Hughes, Timothy P., Branford, Susan, Michor, Franziska
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3156048/
https://ncbi.nlm.nih.gov/pubmed/21653938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-339267
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars